These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37679244)

  • 1. Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534.
    Sung WW
    Eur Urol Oncol; 2024 Feb; 7(1):163. PubMed ID: 37679244
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.
    Montorsi F; Rosiello G; Gandaglia G
    Eur Urol Oncol; 2024 Apr; 7(2):300. PubMed ID: 37838554
    [No Abstract]   [Full Text] [Related]  

  • 3. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
    Tan WS; McElree IM; Davaro F; Steinberg RL; Bree K; Navai N; Dinney CP; O'Donnell MA; Li R; Kamat AM; Packiam VT
    Eur Urol Oncol; 2023 Oct; 6(5):531-534. PubMed ID: 37468392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
    Kates M; Chu X; Hahn N; Pietzak E; Smith A; Shevrin DH; Crispen P; Williams SB; Daneshmand S; Packiam VT; Porten S; Westerman ME; Wagner LI; Carducci M
    Eur Urol Focus; 2023 Jul; 9(4):561-563. PubMed ID: 37422371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.
    Bukavina L; Bell S; Packiam VT; Smaldone M; Abbosh P; Uzzo R; Kutikov A; Correa AF; Magee DE
    Urol Oncol; 2023 Sep; 41(9):391.e1-391.e4. PubMed ID: 37127478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.
    Contieri R; Hensley PJ; Kamat AM
    Eur Urol Oncol; 2024 Apr; 7(2):301. PubMed ID: 37806840
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.
    Kavoussi M; Nasrallah AA; Williams SB
    Eur Urol; 2022 Dec; 82(6):659. PubMed ID: 36089530
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
    McElree IM; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
    JAMA Netw Open; 2023 Feb; 6(2):e230849. PubMed ID: 36853609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.
    Roumiguié M; Black PC
    Eur Urol Focus; 2022 Jul; 8(4):1117-1120. PubMed ID: 34593355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
    Grobet-Jeandin E; Pinar U; Rouprêt M
    Eur Urol Focus; 2022 Jul; 8(4):1121-1123. PubMed ID: 34544673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.
    Ansari Djafari A; Javanmard B; Razzaghi M; Hojjati SA; Razzaghi Z; Faraji S; Rahavian A; Garoosi M
    Urol J; 2023 Feb; 20(2):123-128. PubMed ID: 35689462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
    McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
    J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
    Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
    J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin.
    Meeks JJ; Sexton WJ; Clark PE
    J Urol; 2022 Sep; 208(3):526-527. PubMed ID: 35549526
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Sahoo S; Pandey A; Mandal S; Kumar Das M; Nayak P
    Eur Urol; 2023 Feb; 83(2):e47. PubMed ID: 36404203
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Campodonico F; Mattioli F; Introini C
    Eur Urol; 2023 Feb; 83(2):e56-e57. PubMed ID: 36372625
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonrisk-adapted Sequential Intravesical Gemcitabine and Docetaxel for Nonmuscle-invasive Bladder Cancer: The Time Is Now.
    Steinberg RL; O'Donnell MA; Packiam VT
    J Urol; 2023 Jul; 210(1):5-7. PubMed ID: 37000006
    [No Abstract]   [Full Text] [Related]  

  • 19. Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.
    Velaer KN; Steinberg RL; Thomas LJ; O'Donnell MA; Nepple KG
    Curr Urol Rep; 2016 May; 17(5):38. PubMed ID: 26968418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.